Masculine Foes, Feminist Woes: A Response to Down Girl

In her book, Down Girl, Manne proposes to uncover the “logic” of misogyny, bringing clarity to a notion that she describes as both “loaded” and simultaneously “politically marginal.” Manne is aware that full insight into the “logic” of misogyny will require not just a “what” but a “why.” Though Manne finds herself largely devoted to the former task, the latter is in the not-too-distant periphery. Manne proposes to understand misogyny, as a general framework, in terms of what it does to women. Misogyny, she writes, is a system that polices and enforces the patriarchal social order (33). That’s the “what.” As for the “why,” Manne suggests that misogyny is what women experience because they fail to live up to the moral standards set out for women by that social order. I find Manne’s analysis insightful, interesting, and well argued. And yet, I find her account incomplete. While I remain fully convinced by her analysis of what misogyny is, I am less persuaded by her analysis of why misogyny is. For a full analysis of the “logic” of misogyny, one needs to understand how the patriarchy manifests in men an interest in participating in its enforcement. Or so I hope to motivate here. I aim to draw a line from the patriarchy to toxic masculinity to misogyny so that we have a clearer picture as to why men are invested in this system. I thus hope to offer here an analysis that is underdeveloped in Manne’s book, but is equally worthy of attention if we want fully to understand the complex machinations underlying misogyny

CEO Succession: an Urgent Challenge for Nonprofits

Results of a survey of CEOs and board chairs from nonprofit organizations in Monroe County, NY. They responded to questions about current executive leadership and turnover, what kind of help they need, and important leadership characteristics. Includes links to national studies on the subject of leadership

High speed direct-binary to binary-coded-decimal converter and scaler

Telemetry (pulse code modulated) digital system usually sends binary numbers representing some parameter that is not value of binary number. Received binary number must be scaled and converted to binary coded decimal to operate readout device to display true value. Group of adders speed up binary number conversion and scaling in one operation

The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry

While most economists believe that public scientific research fuels industry innovation and economic growth, systematic evidence supporting this relationship is surprisingly limited. In a recent study, Acemoglu and Linn (2004) identified market size as a significant driver of drug innovation in the pharmaceutical industry, but they did not find any evidence supporting science-driven innovation from publicly funded research. This paper uses new data on biomedical research investments by the U.S. National Institutes of Health (NIH) to examine the contribution of public research to pharmaceutical innovation. The empirical analysis finds that both market size and NIH funded basic research have economically and statistically significant effects on the entry of new drugs with the contribution of public basic research coming in the earliest stage of pharmaceutical drug discovery. The analysis also finds a positive return to public investment in basic biomedical research. --R&D,NIH,social return,biomedical,research lags,public science,new molecular entities

Does Public Scientific Research Complement Industry R&D Investment? The Case of NIH Supported Basic and Clinical Research and Pharmaceutical Industry R&D

This research investigates the hypothesis that publicly funded scientific research complements private R&D investment in the pharmaceutical industry. New microlevel data on public research investment by the U.S. National Institutes of Health allow measures of basic and clinical research in seven medical areas to be included in a distributed lag model explaining pharmaceutical R&D investment. Using a panel of therapeutic classes observed over eighteen years, the analysis finds strong evidence that public basic and clinical research are complementary to pharmaceutical R&D and, thereby, stimulate private industry investment. However, differences in the relevance and degree of scientific and market uncertainty between basic and clinical public research lead to differences in the magnitude and timing of the pharmaceutical investment response. The results indicate that a dollar increase in public basic research stimulates an additional 8.38 in pharmaceutical investment after eight years. The industry R&D response to public clinical research is smaller in magnitude and shorter in duration with a dollar increase in public clinical research stimulating an additional 2.35 in pharmaceutical investment over a three year period. --R&D,pharmaceuticals,NIH,distributed lag models

Biomedical academic entrepreneurship through the SBIR program2.

This paper considers the U.S. Small Business Innovation Research (SBIR) program as a policy fostering academic entrepreneurship. We highlight two main characteristics of the program that make it attractive as an entrepreneurship policy: early-stage financing and scientist involvement in commercialization. Using unique data on NIH supported biomedical researchers, we trace the incidence of biomedical entrepreneurship through SBIR and describe some of the characteristics of these individuals. To explore the importance of early-stage financing and scientist involvement, we complement our individual level data with information on scientist-linked and non-linked SBIR firms. Our results show that the SBIR program is being used as a commercialization channel by academic scientists. Moreover, we find that the firms associated with these scientists perform significantly better than other non-linked SBIR firms in terms of followon venture capital funding, SBIR program completion, and patenting.Academic entrepreneurship; Characteristics; Data; Firms; Information; Innovation;

Exploring the relationship between scientist human capital and firm performance: The case of biomedical academic entrepreneurs in the SBIR Program.

Do academic scientists bring valuable human capital to the companies they found or join? If so, what are the particular skills that compose their human capital and how are these skills related to firm performance? This paper examines these questions using a particular group of academic entrepreneurs - biomedical research scientists who choose to commercialize their knowledge through the U.S. Small Business Innovation Research Program. Our conceptual framework assumes the nature of an academic entrepreneurs' prior research reflects the development of their human capital. We highlight differences in firm performance that correlate with differences in the scientists' research orientations developed during their academic careers. We find that biomedical academic entrepreneurs with human capital oriented toward exploring scientific opportunities significantly improve their firms' performance of research tasks such as 'proof of concept' studies. Biomedical academic entrepreneurs with human capital oriented toward exploring commercial opportunities significantly improve their firms' performance of invention oriented tasks such as patenting. Consistent with prior evidence, there also appears to be a form of diminishing returns to scientifically oriented human capital in a commercialization environment. Holding the commercial orientation of the scientists' human capital constant, we find that increasing their human capital for identifying and exploring scientific opportunities significantly detracts from their firms' patenting performance.Academic entrepreneurship; Biotechnology; Human capital; SBIR program; Firm performance; Performance; Entrepreneurs; SBIR;

Business R&D and the Interplay of R&D Subsidies and Market Uncertainty

The literature suggests that public research and development (R&D) subsidies may reduce market failures affecting private R&D investment caused by incomplete appropriability of knowledge and financial constraints due capital market imperfections. Drawing on the theory of investment under uncertainty, this paper argues that public R&D subsidies increase business R&D investment through an additional mechanism – mitigating the effects of market uncertainty on R&D investment in markets for new products. Using a sample of German manufacturing firms, we show that market uncertainty indeed reduces R&D investment, and that R&D subsidies mitigate the effect of uncertainty. Our findings suggest that public policies aimed at increasing business R&D investment can achieve this objective by reducing the degree of uncertainty in the demand for innovative products. --Real Options Theory,Uncertainty,R&D,Censored Regression

Exploring the relationship between scientist human capital and firm performance: The case of biomedical academic entrepreneurs in the SBIR program

Do academic scientists bring valuable human capital to the companies they found or join? If so, what are the particular skills that compose their human capital and how are these skills related to firm performance? This paper examines these questions using a particular group of academic entrepreneurs – biomedical research scientists who choose to commercialize their knowledge through the U.S. Small Business Innovation Research Program. Our conceptual framework assumes the nature of an academic entrepreneurs? prior research reflects the development of their human capital. We highlight differences in firm performance that correlate with differences in the scientists? research orientations developed during their academic careers. We find that biomedical academic entrepreneurs with human capital oriented toward exploring scientific opportunities significantly improve their firms? performance of research tasks such as ?proof of concept? studies. Biomedical academic entrepreneurs with human capital oriented toward exploring commercial opportunities significantly improve their firms? performance of invention oriented tasks such as patenting. Consistent with prior evidence, there also appears to be a form of diminishing returns to scientifically oriented human capital in a commercialization environment. Holding the commercial orientation of the scientists? human capital constant, we find that increasing their human capital for identifying and exploring scientific opportunities significantly detracts from their firms? patenting performance. --Academic Entrepreneurship,SBIR Program,Human Capital,Biotechnology

Biomedical Academic Entrepreneurship Through the SBIR Program

This paper considers the U.S. Small Business Innovation Research (SBIR) program as a policy fostering academic entrepreneurship. We highlight two main characteristics of the program that make it attractive as an entrepreneurship policy : early-stage financing and scientist involvement in commercialization. Using unique data on NIH supported biomedical researchers, we trace the incidence of biomedical entrepreneurship through SBIR and describe some of the characteristics of these individuals. To explore the importance of early-stage financing and scientist involvement, we complement our individual level data with information on scientist-linked and non-linked SBIR firms. Our results show that the SBIR program is being used as a commercialization channel by academic scientists. Moreover, we find that the firms associated with these scientists perform significantly better than other non-linked SBIR firms in terms of followon venture capital funding, SBIR program completion, and patenting. --Academic entrepreneurship,star scientists,SBIR,Venture Capital,innovation